NOMAD-FOODS
9.5.2022 11:43:08 CEST | Business Wire | Press release
Nomad Foods, Europe’s leading frozen food company, which owns brands including Birds Eye, Findus and iglo, is calling on the food industry and regulators across Europe to consider a more comprehensive, end-to-end approach to Life Cycle Assessment (LCA) studies, which includes food loss and waste impacts, to improve transparency for consumers and drive critical action to reduce carbon emissions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005425/en/
Food production is a major contributor to climate change and making better environmental choices about what we eat and how we reduce food waste is one way for businesses and consumers to lower their carbon impact. To support this action, it’s vital that food companies fully understand their products’ total emissions footprint and provide clear, accurate and complete information.
With carbon labels and previous LCA studies on food often limited in scope, Nomad Foods has recently enlisted the help of international experts in impact assessments, PRé Sustainability, to conduct a unique end-to-end LCA study for 22 of Nomad Foods’ most popular products1 .
Crucially, the study went beyond the scope of existing LCAs to include all stages of the product life cycle, incorporating new data on retailer and consumer food waste (an important element of Scope 3 emissions for food manufacturers) and primary data for all processing steps, improving the accuracy of the assessment – with the results peer reviewed by leading experts.
The study showed that retail and consumer food loss and waste – data which is not generally included in previous LCA assessments of food – plays an important part of the product life cycle and has a significant effect on a product’s overall environmental impact. In fact, retail and consumer food waste equates to an estimated 160m tonnes and 17.25m tonnes of CO2 in the EU and UK respectively2 .
This new assessment means that, for the first time ever, clear conclusions can be drawn about the carbon footprint of frozen foods products and meaningful comparisons made to their non-frozen alternatives, while accounting for all relevant and material impacts. Results for the 22 frozen products assessed under the new study showed that most had an equal or lower carbon footprint than similar products using other preservation methods.
Stéfan Descheemaeker, Chief Executive Officer, Nomad Foods, said: “Consumer demand for nutritious, high-quality, sustainable food is growing and we believe it’s vital that we find ways to provide consumers with information that helps them make informed choices and provides confidence that sustainability claims are robust and evidence-based. To support this, we encourage the food industry, retailers and regulators to adopt a wider scope for LCAs as standard, taking the whole product life cycle into account. Based on the ground-breaking work that our teams have undertaken with life cycle experts PRé Sustainability, we can see there are significant benefits to frozen food in terms of longer-term food preservation and reduced food waste.”
Ellen Meijer, Consultant, PRé Sustainability, said: “This is one of the most elaborate frozen food LCA studies ever done, covering not only a wide range of frozen food products and their alternatives, but also approaching them all in a consistent methodological manner. Combined with the large amount of primary production data included and the attention to detail at each stage, this study is one of a kind. Based on this study, we are now in the unique position to draw conclusions about the carbon footprint of frozen food products compared to their non-frozen alternatives and generalize these conclusions across the frozen food category."
About Nomad Foods
Nomad Foods (NYSE: NOMD) is Europe’s leading frozen food company. The company's portfolio of iconic brands, which includes Birds Eye
, Findus
, iglo
, Ledo
and Frikom
, have been a part of consumers' meals for generations, standing for great tasting food that is convenient, high quality and nutritious. Nomad Foods is headquartered in the United Kingdom. Additional information may be found at www.nomadfoods.com
.
About PRé Sustainability
For thirty years PRé Sustainability has been at the forefront of life cycle thinking and has built on its knowledge and experience in sustainability metrics and impact assessments to provide state of the art methods, consulting services and software tools. Internationally, leading organizations work with PRé to integrate sustainability into their product development procedures in order to create business growth and business value. PRé has an office in the Netherlands and a global partner network to support large international or multi-client projects. www.pre-sustainability.com
.
Notes to Editors:
1 The comprehensive LCA study covered 10 keys stages. Stages 6 – 10 are the extended scope of the assessment not generally included in other studies :
- Ingredients : Production, including transport to factory.
- Processing : All activities that happen at the factory including energy, on-site waste and the treatment of it, and activities related to packaging the product. Also includes any pre-blanching or pre-freezing before it reaches the factory. The study included primary data for all material processes improving the accuracy of the assessment.
- Packaging : Packaging materials, including their transport to the factory.
- Distribution : Transport from the factory, storage at the distribution centre, transport to the retail hub and storage at the retail hub.
- Retail storage : Electricity and coolant use in the retail cold room and on the retail floor.
- Retail waste : Waste treatment of transport packaging, product losses and waste treatment of product losses, including processing, packaging and distribution of the product losses.
- Consumer transport : From the retailer to the consumer.
- Consumer storage : Electricity use for storage at the consumer.
- Consumer preparation : Energy use at the consumer to cook the food product, as well as any capital goods.
- Consumer waste : Waste treatment of primary packaging and product losses. This includes all upstream processes required to compensate for the product losses at the consumer.
2 6.9m tonnes of the UK’s annual total of 9.5m tonnes of food waste is down to the retailer and consumer, equivalent to 17.25m tonnes of CO2 (WRAP). In the EU the retail and consumer proportion of the 88m tonnes of food waste generated, equates to 160m tonnes of CO2. Calculation based on 1 kg of food waste creates 2.5 kg of CO22013; Food Wastage Footprint Impact on Natural Resources; United Nation’s Food & Agriculture Organization
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005425/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
